GenMark Diagnostics (NASDAQ:GNMK) has come to the conclusion that it needs to widen its equity base. The company announced that it aims to float a $60 million issue of its common stock. Additionally, it intends to grant the issue's underwriter a 30-day option to purchase up to an additional $9 million worth of shares.
GenMark said it plans to use the proceeds of the offering for general corporate purposes. These include research, development, and investment activities.
JPMorgan Chase's J.P. Morgan Securities is the sole book-running manager of the issue.
At the moment, GenMark has 32.7 million shares outstanding, and its stock most recently closed at $9.72 per share.
Fool contributor Eric Volkman has no position in any stocks mentioned. The Motley Fool owns shares of JPMorgan Chase. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Why GenMark Diagnostics, Inc. Is Soaring Today
Shares jump in response to an analyst upgrade.
3 Horrendous Health-Care Stocks This Week
Big market losses this week? They're just pocket change compared with what these horrendous stocks experienced.
Why GenMark Diagnostics Shares Slumped
GenMark lowers the bar, and so do investors.